Journal Article

Triple-negative breast cancer molecular subtyping and treatment progress

Duan, Jiang-Jie, Yu, Shi-cang, Yin, Li, Bian, Xiu-Wu

2020

Overview

Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. By summarizing existing treatment regimens, therapeutic drugs, and their efficacy for different TNBC subtypes and reviewing some new preclinical studies and targeted treatment regimens for TNBC, this paper aims to provide new ideas for TNBC treatment.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Androgens / Antimitotic agents / Antineoplastic agents / Biomedical and Life Sciences / Biomedicine / Breast cancer / Cancer / Cancer Research / Cancer therapies / Care and treatment / Cell adhesion & migration / Cell cycle / Chemotherapy / DNA repair / Drug therapy / Drugs / Endocrine therapy / Epidermal growth factor / ErbB-2 protein / Estrogen / Estrogen receptors / Ethnicity / Gene expression / Growth factors / Health aspects / Hispanic people / Invasiveness / Kinases / Medical prognosis / Metabolism / Metastases / Metastasis / Molecular subtype / Mortality / Oncology / Patients / Progesterone / Review / Signal transduction / Surgical Oncology / T cell receptors / Therapeutic regimen / Therapeutic target / Triple-negative breast cancer / Tumors / Womens health